医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Discounted Chinese Market Research Reports by AMID Now Available at MarketPublishers.com

2012年11月22日 PM08:55
このエントリーをはてなブックマークに追加


 

LONDON

Market Publishers Ltd is happy to announce a flat 50% discount on all AMID research reports covering a diverse range of markets and industries in China.

The Chinese rapidly growing economy is bound to provide a significant boost for

ninety-nine out of a hundred various local industries in years to come, in terms of both production and consumption.

Market Research Reports on Offer Include but Are Not Limited to:

These discounted research reports are aimed at providing tangible insights and analyses into the pertinent Chinese markets. For all the industries covered, the reports feature economic trends, investment environment, industry development, supply and demand dynamics, industry capacity and structure, marketing channels and major players active in the industry. Historical data (2001, 2006 and 2011) and elaborate forecasts through 2016 and 2021 are provided for all the markets under consideration. Extensive profiles the top companies as well as other relevant and worthy of note information can be found in each market analysis, too.

The offer is valid until December 31, 2012!

Full list of AMID’s market research reports on offer can be found at http://marketpublishers.com/members/amidco/info.html

CONTACT

The Market Publishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax:
+44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表